Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19099588 | 0.75 | CPA1 (0.39) | CPA1CPB2 | |
| SCHEMBL21028246 | 0.75 | CPA1 (0.34) | CPA1CPB2 | |
| SCHEMBL21340911 | 0.74 | CPA1 (0.36) | CPA1CPB2 | |
| SCHEMBL20756433 | 0.71 | CPA1 (0.40) | CPA1CPB2 | |
| SCHEMBL6124223 | 0.71 | — | — | |
| SCHEMBL20903985 | 0.64 | CPA1 (0.37) | CPA1CPB2 | |
| SCHEMBL12039663 | 0.64 | CPA1 (0.41) | CPA1CPB2 | |
| SCHEMBL28807920 | 0.63 | — | — | |
| SCHEMBL22993471 | 0.63 | — | — | |
| SCHEMBL19254150 | 0.61 | CPA1 (0.32) | CPA1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | AZI2, FURIN, ACE2 | CPA1 290/4885CPB2 131/4885 |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | AZI2, FURIN, ACE2 | CPA1 290/4885CPB2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.